KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Research & Development: 2015-2025

Historic Research & Development for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to $58.9 million.

  • CRISPR Therapeutics AG's Research & Development fell 28.31% to $58.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $283.4 million, marking a year-over-year decrease of 15.05%. This contributed to the annual value of $320.7 million for FY2024, which is 17.21% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Research & Development of $58.9 million as of Q3 2025, which was down 15.73% from $69.9 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Research & Development ranged from a high of $123.2 million in Q2 2022 and a low of $58.9 million during Q3 2025.
  • Over the past 3 years, CRISPR Therapeutics AG's median Research & Development value was $82.2 million (recorded in 2024), while the average stood at $82.7 million.
  • Its Research & Development has fluctuated over the past 5 years, first spiked by 180.14% in 2021, then decreased by 28.31% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Research & Development (Quarterly) stood at $103.1 million in 2021, then increased by 0.45% to $103.6 million in 2022, then dropped by 8.12% to $95.1 million in 2023, then decreased by 13.65% to $82.2 million in 2024, then decreased by 28.31% to $58.9 million in 2025.
  • Its Research & Development was $58.9 million in Q3 2025, compared to $69.9 million in Q2 2025 and $72.5 million in Q1 2025.